Advertisement

PACB

Pacific Biosciences of California, Inc.

Healthcare · USD

Set alert

Price alert · PACB

All alert types
2.61 USD -0.29 -10.17%
As of Oct 30, 2026 Extended hours 2.66 +2.11%
Bid
2.60 × 2
Ask
2.61 × 2
2.41 Day range 2.82
1.11 52-week range 2.90
YTD
+39.30%
1 year
+34.28%
Open
2.75
Prev close
2.90
Mkt cap
809.71M
Vol
13.74M
Avg vol
11.85M
EPS
-0.43
P/E
0.00
Div yield
0.00%
More statistics
Low
2.41
High
2.82
Forward P/E
-2.84
Beta
2.01
Short ratio
4.46
Inst. own
84.53%
Dividend
0.00
Ex-div date
50-d avg
2.01
200-d avg
2.02
1y target
3.02

5D chart

Chart tools
Interval
PACB five-day price chart2.082.332.582.823.07Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
568.03M
Enterprise value
989.12M
Trailing P/E
0.00
Forward P/E
-2.84
PEG ratio
0.00
Price / sales
3.28
Price / book
1.17
EPS (TTM)
-1.46
Beta
2.01
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-227.69%
Revenue (TTM)
173.15M
Revenue growth
-28.20%
Free cash flow
-190.76M
Total cash
471.15M
Total debt
920.75M
Return on equity
-64.80%
Shares outstanding
294.32M
Short % of float
21.05%
50-day average
2.01
200-day average
2.02

Analyst view

Consensus: buy

Buy
Price target (mean) 3.02 +16.0% upside
Target (low)
2.00
Target (mean)
3.02
Target (high)
6.00
Ratings (0m) 15 7 buy · 8 hold · 0 sell
  • Strong buy1
  • Buy6
  • Hold8
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate -0.17551.

Earnings history

Financials — quick view

All financials
PACB Revenue — quarterly 39.01M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PACB Net income — quarterly -44.74M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PACB EPS — quarterly -0.14
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PACB recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.20-0.17+0.03+15.00%
Aug 7, 2024Jun 1, 2024-0.24-0.20+0.04+16.67%
May 9, 2024Mar 1, 2024-0.26-0.260.000.00%
Feb 15, 2024Dec 1, 2023-0.31-0.27+0.04+12.90%
Oct 30, 2023Sep 1, 2023-0.30-0.27+0.03+10.00%
Aug 2, 2023Jun 1, 2023-0.34-0.26+0.08+23.53%

Upgrades / downgrades

PACB analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2024UBSdownBuyNeutral
Nov 11, 2024ScotiabankmainSector OutperformSector Outperform
Nov 11, 2024Piper SandlermainNeutralNeutral
Aug 28, 2024ScotiabankmainSector OutperformSector Outperform
Aug 13, 2024Stephens & Co.mainOverweightOverweight
Aug 12, 2024Morgan StanleymainEqual-WeightEqual-Weight

About Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States
Website
pacb.com

News

Your note

Sign in to keep a note on PACB — it syncs with the Stock Master app.

Insider holders

PACB insider holders
InsiderRelationLatest transactionDateShares held
EIDEL JEFFREYOfficerSaleAug 18, 2024869,938
ERICSON WILLIAM WDirectorStock Award(Grant)Jun 17, 202441,616
HENRY CHRISTIAN OChief Executive OfficerSaleSep 15, 20242,497,760
KIM SUSAN GChief Financial OfficerSaleSep 29, 2024695,654
LIVINGSTON RANDALL SDirectorStock Award(Grant)Jun 17, 202422,821
MILLIGAN JOHN FDirectorStock Award(Grant)Jun 17, 2024132,821

Institution ownership

PACB institution ownership
Holder% heldSharesValueReported
ARK Investment Management, LLC12.20%33,406,40164.47MSep 29, 2024
Madrone Advisors, LLC 8.54%23,391,91545.15MSep 29, 2024
Blackrock Inc.8.49%23,252,68244.88MSep 29, 2024
Edmond De Rothschild Holding S.A.7.42%20,307,88039.19MSep 29, 2024
Vanguard Group Inc6.44%17,642,80434.05MSep 29, 2024
Sumitomo Mitsui Trust Holdings, Inc.4.33%11,865,76622.90MSep 29, 2024

Fund ownership

PACB fund ownership
Holder% heldSharesValueReported
ARK ETF Tr-ARK Innovation ETF6.91%18,937,39736.55MOct 30, 2024
ARK ETF Tr-ARK Genomic Revolution ETF4.52%12,389,94423.91MOct 30, 2024
Vanguard Total Stock Market Index Fund3.26%8,930,67917.24MSep 29, 2024
iShares Russell 2000 ETF2.57%7,047,50013.60MOct 30, 2024
Vanguard Extended Market Index Fund1.45%3,984,4977.69MSep 29, 2024
Smallcap World Fund1.24%3,390,0006.54MSep 29, 2024
Advertisement